DOCSLIB.ORG

Alcohol Based Anti-Microbial Compositions with Cosmetic Appearance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alcohol Based Anti-Microbial Compositions with Cosmetic Appearance Patentamt Europaisches ||| || 1 1| || || || 1 1| || || || || 1 1| (19) J European Patent Office Office europeen des brevets (11) EP 0 930 065 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51 ) |nt. CI.6: A61 K 7/48, A61 K 7/50, 21.07.1999 Bulletin 1999/29 ^61 |_ 2/Q0 (21) Application number: 99300394.6 (22) Date of filing : 20.01 .1 999 (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU • Jampani, Hanuman J. MC NL PT SE Grapevine, TX 76051 (US) Designated Extension States: • Newman, Jerry L. AL LT LV MK RO SI Arlington, TX 7601 6 (US) • Newman, Anthony W. (30) Priority: 20.01.1998 US 9491 Fort Worth, TX 761 1 1 (US) (71) Applicant: ETHICON INC. (74) Representative: Somerville New Jersey 08876 (US) Mercer, Christopher Paul et al Carpmaels & Ransford 43, Bloomsbury Square London WC1 A 2RA(GB) (54) Alcohol based anti-microbial compositions with cosmetic appearance (57) The present invention provides antimicrobial compositions containing high levels of alcohol, car- bomer polymers and antimicrobial agents. The present invention provides stable, high viscosity antimicrobial formulations possessing cosmetic characteristics. CM < LO CO o o CO o Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 EP 0 930 065 A2 Description [0001] This application is related to European patent application No. (claiming priority from USSN 09/009 489 - Attorney's ref: P020733EP) and European patent application No. (claiming 5 priority from USSN 09 -Attorney's ref: ) the disclosures of which are incorporated herein by reference. [0002] The present invention relates to anti-microbial compositions, more particularly to alcohol-containing cationic antimicrobial compounds that are compatible with emollients and cationic compounds thereby providing lotion-like appearance and properties. 10 BACKGROUND OF THE INVENTION [0003] Alcohols and alcohol-containing mixtures are known to possess bactericidal activity and to prevent nosocomial infections in hospital settings between patients, nurses and doctors. The use of alcohol based compositions is declining 15 due to their inherent dehydrating properties which is caused by the denaturing and delipidizing of the skin's lipid mole- cules. It is appreciated in the art that lipids in stratum corneum of the skin are important in the barrier properties. [0004] In an attempt to address the dehydration and delipidization problem, attempts have been made to minimize the dehydration effects of the alcohol systems. US Patent Number 5,288,486 discloses the use of polymeric viscosifying agents which have been added to the compositions to reduce evaporation and provide moisturization. While this 20 approach has reduced the evaporation rate of the alcohol, the [0005] It would be highly desirable to provide an effective alcohol-containing antimicrobial composition that possesses the feel and moisturizing attributes of a hand cream and lotion. It is also desirable to use chemical ingredients that pro- vide the appearance of moisturizing products to overcome the perceived drying of topical alcohol-containing formula- tions. These two aspects in any product or a formulation would provide multi-functions, such as antibacterial efficacy, 25 mildness, moisturization and protection. SUMMARY OF THE INVENTION [0006] The present invention provides a highly effective antimicrobial composition that also possesses moisturizing 30 attributes and does not become greasy to the touch. In particular, one aspect of the invention provides an aqueous anti- microbial composition comprising alcohol, an effective amount of a antimicrobial compound, particularly cationic com- pounds, and a carbomer polymer, the composition having a viscosity of greater than 5,000 centipoise. [0007] In a second embodiment of the invention the antimicrobial composition additionally is provided with an effective amount of phenylethyl dimethicone, stearoxytrimethylsilane and stearyl alcohol to provide an opaque, milky white 35 lotion. [0008] In a third embodiment of the invention the antimicrobial formulation additionally contains an effective amount of cetyl lactate and (C12-C15) alkyl lactates and/or an effective amount of cyclomethicone. The addition of these ingre- dients allows the formulation to incorporate more essential oils and volatile compounds which improves the overall per- formance of the composition. 40 [0009] Another embodiment of the present invention provides a method for disinfecting surfaces by contacting the sur- face with an effective amount of the antimicrobial composition. DETAILED DESCRIPTION OF THE INVENTION 45 [001 0] The present invention relates to antimicrobial alcohol-containing compositions containing a carbomer polymer, a cationic antimicrobial compound and a preferably a silicone wax. A complexing agent may additionally be provided. The balance of the composition is water, typically from about 15 to about 40 percent by weight. [0011] The alcohols useful in the present invention include n-propyl and /so-propyl alcohol and ethyl alcohol. The alcohols are typically employed at a level of from about 40 to about 80 percent by volume, preferably from about 60 to so about 75 percent by volume. Ethyl alcohol is typically used in the present invention from about 20 to about 55 weight percent, preferably from about 30 to about 50 and most preferably from about 35 to about 48 weight percent. When a mixture of alcohols are employed ethyl alcohol is typically used from 20-55 weight percent, /so-propyl alcohol from about 5 to about 30 weight percent and n-propyl alcohol from about 2 to about 40 weight percent. More preferably the amount of ethyl alcohol is from about 30 to about 50 weight percent, /so-propyl alcohol from about 8 to about 20 weight 55 percent and n-propyl alcohol from about 4 to about 20 weight percent. [0012] The antimicrobial cationic compositions suitable for use in the present invention include cationic compounds which are well know in the art. Suitable compounds include benzethonium chloride, benzalkonium chloride, cetyl pyrid- inium chloride, bisdequalinium chloride, cetylalkonium benzethonium chloride, benzalkonium chloride, cetyl pyridinium 2 EP 0 930 065 A2 chloride, bisdequalinium chloride, cetylalkonium chloride, methyl benzethonium chloride, phenoctide, tibezonium iodide, triclobisonium chloride, laurolinium acetate, mixtures thereof and the like. The present invention overcomes the destability problem encountered when cationic compounds are mixed with carbomer polymers. The total cationic com- pound level is typically from about 0.05 to about 0.5, preferably from about 0.08 to about 0.3 percent by weight, and 5 most preferably from about 0.09 to about 0.2 weight percent. [001 3] The present invention also employs thickening agents of acrylic acid which are crosslinked with an unsaturated polyfunctional agent such as polyallyl ether of sucrose. These acrylic acid functionalized polymers, commonly known as carbomers, are disclosed in US Pat. Nos. 2,798,053 and 3,133,865 herein incorporated by reference. [0014] The selection of the proper carbomer provides the antimicrobial formulation with the desired viscosity values. 10 In order to have the desired feel the viscosity of the formulation must have a value of greater than about 5,000 centipoise. More preferably the formulations will have a viscosity of from about 9,000 to about 22,000 and most prefer- ably from about 1 1 ,000 to about 20,000 centipoise as measured at 25°C. [001 5] A thickening agent, which is an addition agent comprised of an acrylic acid polymer crosslinked with an unsatu- rated polyallyl ether of sucrose is employed. The polymers are used in an amount sufficient to obtain a gelled compo- 15 sition of viscosity in the desired range. [0016] A number of these polymers, known in the art as carbomers are commercially marketed by B.F. Goodrich, (Cleveland, Ohio) such as CARBOPOL® 934, 940 and 941; and by R.l.T.A. (Crystal Lake, IL)as ACRITAMER® 934,940 and 941 , respectively. Typically the carbomer compounds are used from about 0.2 to about 2.0 percent by weight, and are preferably employed at a level of from about 0.4 to about 0.7 by weight of the total antimicrobial com- 20 position. [0017] A preferred carbomer polymer, among several preferred carbomers, is R.l.T.A. ACRITAMER® 505E, a polyvi- nyl carboxy polymer crosslinked with ethers of pentaerythritol. ACRITAMER® 505E is preferred as a gelling agent or viscosity enhancer because it provides a transparent or translucent gel in the present invention. [0018] The most preferred carbomer is ULTREZ® 10 (available from BF Goodrich)an oil in water emulsion of a mod- 25 if ied acrylic copolymer comprising of a major portion of a monoolef inically unsaturated carboxylic acid monomer or its anhydride having a length of from about 3 to 6 carbon atoms and a minor portion of a C8-C30 chain acrylate or meth- acrylate ester monomer wherein the carboxylic acid or its anhydride is from about 80 to about 99% by weight and the a C8-C30 chain acrylate or methacrylate ester monomer is from about 1% to about 20% by weight. The polymer is described in US Pat. Number 5,004,598, hereby incorporated by reference in its entirety. 30 [001 9] The present invention provides surprising and unexpected results in that contrary to the disclosure provided in its literature, ULTREZ® 10 provides excellent viscosity in the presence of ions. This is surprising in that ULTREZ® 10 product literature discloses that the product is not stable, and should be used in combination residue on the skin that is overly sticky and has acceptable tactile characteristics. Suitable agents are known in the art and include gums, substi- tuted gums such as propylene glycol ether of guar gums, xanthan gum and the like. 35 [0020] In addition to the above identified materials in the formulation it is highly desirable to include other ingredients in order to enhance the performance or feeling of the composition.
Load more

Recommended publications
  • Quaternary Ammonium Compounds
    FACT SHEET: Quaternary Ammonium Compounds Quaternary ammonium compounds, also known as “quats” or “QACs,” include a number of chemicals used as sanitizers and disinfectants, including benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, ammonium chloride, and stearalkonium chloride.[i] In general, quats cause toxic effects through all Mutagenicity routes of exposure including inhalation, Some quats have shown to be mutagenic and to ingestion, dermal application, and irrigation of damage animal DNA and DNA in human body cavities. Exposure to diluted solutions may lymphocytes at much lower levels than are result in mild irritation, while concentrated present in cleaning chemicals.[6] solutions are corrosive, causing burns to the skin and mucous Membranes. They can produce Antimicrobial Resistance systemic toxicity and can also cause allergic Genes have been discovered that mediate reactions.[2] resistance to quats. There has been an association of some of these genes with beta lactamase genes, Asthma and Allergies raising concern for a relationship between Of particular interest with regard to use as disinfectant resistance and antibiotic resistance.[7] disinfectants in the COVID-19 pandemic, quats increase the risk for asthma and allergic Reproductive Toxicity sensitization. Evidence from occupational Mice whose cages were cleaned with QACs had exposures shows increased risk of rhinitis and very low fertility rates. [8] Exposure to a common asthma
    [Show full text]
  • FDA-2015-N-0101; and FDA-2016-N-0124
    DE PARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 November 18, 2020 Docket Nos. FDA-1975-N-0012; FDA-2015-N-0101; and FDA-2016-N-0124 The American Cleaning Institute Attention: James Kim, PhD Vice President, Science and Regulatory Affairs 1401 H Street, N.W. Suite 700 Washington, D.C. 20005 Re: Benzalkonium Chloride, Benzethonium Chloride, Chloroxylenol, Ethanol, and Povidone-Iodine Dear Dr. Kim: This letter responds to The American Cleaning Institute’s (ACI’s) July 14, 2020 communication regarding the deferral from final rulemaking under the over-the-counter (OTC) Drug Review on benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine for use in nonprescription (often referred to as over-the-counter or OTC) consumer antiseptic wash, health care antiseptic, and consumer antiseptic rub drug products. In March 2016, FDA issued letters granting requests to defer three active ingredients— benzalkonium chloride, benzethonium chloride, and chloroxylenol—from inclusion in the final rulemaking for the December 2013 proposed rule for OTC consumer antiseptic washes (78 FR 76444). Similarly, in January 2017, FDA issued letters granting requests to defer six active ingredients—benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, povidone- iodine, and isopropyl alcohol—from inclusion in the final rulemaking for the May 2015 proposed rule for OTC health care antiseptics (80 FR 25166). In October 2017, FDA issued letters granting requests to defer three active
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Wo 2010/127231 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 November 2010 (04.11.2010) WO 2010/127231 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every AOlN 33/12 (2006.01) A61K 31/14 (2006.01) kind of national protection available): AE, AG, AL, AM, AOlN 25/04 (2006.01) CIlD 3/26 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, AOlP 1/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US2010/033 148 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 30 April 2010 (30.04.2010) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/174,724 1 May 2009 (01 .05.2009) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): SIG¬ TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, NAL INVESTMENT AND MANAGEMENT CO.
    [Show full text]
  • Benefits of Benzalkonium Chloride Based Hand Sanitizers
    Benzalkonium chloride-based Hand Sanitizers have distinct advantages over gelled alcohol hand sanitizers. While both product forms are FDA Monograph compliant for leave on products, fast acting and allow for use without water or towels, benzalkonium chloride-based products are non-flammable, less drying to skin, and will not stain clothing. Published studies report that benzalkonium chloride based hand sanitizers demonstrated greater sustained degerming activity than gelled alcohol gel hand sanitizers that actually became less effective with repeated use and made the skin dirtier, not cleaner due to removal of protective natural skin oils and entrapment of dead skin cells by the polymer thickeners used in the gelled alcohol products (AORN Journal, (68 August 1998), p. 239-251). Benzalkonium chloride, unlike benzethonium chloride, is the only quat active ingredient with a history of use in leave-on, FDA Monograph anti-bacterial skin treatment products. Leave-on Hand Sanitizers should not be used as a substitute for proper hand washing and hygiene practices. Patented Non-Alcohol Instant Foaming Hand Sanitizer produces a fast drying, non-sticky foam that contains unique non-drying, conditioning and moisturizing ingredients, leaves the skin with a soft, refreshing and silky after feel, and does not contain polymer thickeners or silicones. Multiple Instant Foam Hand Sanitizer, based on the active ingredient Benzalkonium chloride, featuring exceptional skin feel, conditioning and moisturizing properties. The efficacy of these product have been confirmed to reduce S. aureus 99.9999% in as little as 15 seconds. All of the Instant Foam Hand Sanitizer are in compliance with the FDA Final Tentative Monograph for OTC Hand Sanitizer preparations (leave-on sanitizers not requiring a rinse), and most are registered in Canada.
    [Show full text]
  • Comparative Study of Bactericidal Activities of Six Different Disinfectants
    Nagoya J. Mod. Sci. 47. 101 ~ 112. 1985 COMPARATIVE STUDY OF BACTERICIDAL ACTIVITIES OF SIX DIFFERENT DISINFECTANTS YOSHIMICHI NAMBA*, ASAKATSU SUZUKI*, NOBORU TAKESHIMA** and NOBUO KATO*** * Department of Surgical Center, Nagoya Universi/y Hospital, and ** Deparlment of Anes/hesiology and *** Depar/ment of BaCieriology, Nagoya Universi/y School of Medicine Nagoya 466, Japan ABSTRACT Bactericidal activities of six commonly used disinfectants against scven different species of clinically isolatcd hacteria, mainly glucose-nonfermentative Gram-negative hacilli, were compared. In terms of mean values of the minimum hactericidal concentration (M BC), henzethonium chloride showed the highest efficacy, followed in order hy chlorhexidine gluconate, alkyldiaminoethylglycine hydrochloride, glutaraldehyde, povidone-iodine, and phenol. However, mean MBCs of henzethonium chloride, alkyldiaminoethylglycine hydrochloride and chlorhexidine gluconate against individual species covered a far wider range from species to species compared with those of the other three disinfectants. In addition, hactericidal activities of the ahove-mentioned three disinfectants against Pseudomonas cepacia and Achrolllohaetcr xrlosoxidans ranged more widely from strain to strain than against other species. When the minimum concentrations of individual disinfectants recommended for hospital use hy the manufacturers were used, chlorhexidine gluconate (0.02%), alkyldiaminoethylglycine hydrochloride (0.1%), henzethonium chloride (0.1%) and povidone-iodine (0.75%) were not hactericidal to definite numhers of hacterial strains tested. Among them, chlorhexidine gluconate at the concentration recommended was ineffective against many strains of all hacterial species tested, especially against strains of glucose-nonfermentative Gram-negative hacilli except for PseW/O/llOllaS aerugillosa. Alkyldiamino­ ethylglycine hydrochloride was also remarkahly ineffective against Staphylococcus aI/reus and P. cepacia. Among all the species tested, P.
    [Show full text]
  • Assessment of Spermicides by a Stripping Technique Against Human
    Assessment of spermicides by a stripping technique against human spermatozoa Janet Brotherton Department of Gynaecological Endocrinology, Sterility and Family Planning, Klinikum Steglitz of the Free University Berlin, Hindenburgdamm 30,1000 Berlin 45, Germany Summary. Fifty-two (52) compounds were tested for spermicidal activity by titration against human spermatozoa. The gradual decrease in mean sperm size was measured against increasing concentration of spermicide and the end-point was taken as the point at which all the peripheral cytoplasm had been removed and only the sperm core of nucleus and tail fibres remained. There were 14 compounds that produced this total effect. All were detergents, of various types, and the effect was purely physical. The most potent compounds caused complete stripping at 0\m=.\5\p=n-\50pmol/cell and most are already used in spermicidal preparations. A further 11 compounds, including sodium hypochlorite and some phenols, caused partial stripping, while 4 compounds caused sperm swelling. The test was not suitable for assessment of metabolic cell poisons. Introduction The methods of assessment and the types of potent spermicides have been reviewed by Bernstein (1974). The usual method of measuring the cytotoxic potencies of compounds against specific cell types is to measure the degree of inhibition of growth, i.e. of cell division. This method cannot be used to assess the potency of spermicides and it has been usual to measure some morphological or biochemical sperm characteristic as the end-point, e.g. the decrease in percentage of motile sperma¬ tozoa after a set time or the time taken for all the spermatozoa to become immotile.
    [Show full text]
  • FDA Warns About Rare but Serious Allergic Reactions with the Skin Antiseptic Chlorhexidine Gluconate
    FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconate Safety Announcement [2-2-2017] The U.S. Food and Drug Administration (FDA) is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. Although rare, the number of reports of serious allergic reactions to these products has increased over the last several years. As a result, we are requesting the manufacturers of over-the-counter (OTC) antiseptic products containing chlorhexidine gluconate to add a warning about this risk to the Drug Facts labels. Prescription chlorhexidine gluconate mouthwashes and oral chips used for gum disease already contain a warning about the possibility of serious allergic reactions in their labels. Patients and consumers should stop using the product that contains chlorhexidine gluconate and seek medical attention immediately or call 911 if they experience symptoms of a serious allergic reaction. These reactions can occur within minutes of exposure. Symptoms include wheezing or difficulty breathing; swelling of the face; hives that can quickly progress to more serious symptoms; severe rash; or shock, which is a life-threatening condition that occurs when the body is not getting enough blood flow. Health care professionals should always ask patients if they have ever had an allergic reaction to any antiseptic before recommending or prescribing a chlorhexidine gluconate product. Advise patients to seek immediate medical attention if they experience any symptoms of an allergic reaction when using the products. Consider using alternative antiseptics such as povidone-iodine, alcohols, benzalkonium chloride, benzethonium chloride, or parachlorometaxylenol (PCMX) when any previous allergy to chlorhexidine gluconate is documented or suspected.
    [Show full text]
  • 60474 Federal Register/Vol. 82, No. 243/Wednesday, December 20
    60474 Federal Register / Vol. 82, No. 243 / Wednesday, December 20, 2017 / Rules and Regulations DEPARTMENT OF HEALTH AND SUPPLEMENTARY INFORMATION: ingredients are benzalkonium chloride, benzethonium chloride, chloroxylenol, HUMAN SERVICES Table of Contents alcohol (also referred to as ethanol or Food and Drug Administration I. Executive Summary ethyl alcohol), isopropyl alcohol, and A. Purpose of the Final Rule povidone-iodine. Accordingly, FDA 21 CFR Part 310 B. Summary of the Major Provisions of the does not make a GRAS/GRAE Final Rule determination in this final rule for these [Docket No. FDA–2015–N–0101] C. Costs and Benefits six active ingredients for use as OTC RIN 0910–AH40 II. Table of Abbreviations and Acronyms health care antiseptics. The monograph Commonly Used in This Document or nonmonograph status of these six Safety and Effectiveness of Health III. Introduction A. Terminology Used in the OTC Drug ingredients will be addressed, either Care Antiseptics; Topical Antimicrobial Review Regulations after completion and analysis of ongoing Drug Products for Over-the-Counter B. Topical Antiseptics studies to address the safety and Human Use C. This Final Rule Covers Only Health Care effectiveness data gaps of these Antiseptics ingredients or at a later date, if these AGENCY: Food and Drug Administration, IV. Background studies are not completed. HHS. A. Significant Rulemakings Relevant to This rulemaking finalizes the ACTION: Final rule. This Final Rule nonmonograph status of the remaining B. Public Meetings Relevant to This Final 24 active ingredients intended for use in SUMMARY: The Food and Drug Rule health care antiseptics identified in the Administration (FDA, the Agency, or C.
    [Show full text]
  • Benzethonium Chloride: a Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen Kenneth W
    Cancer Therapy: Preclinical Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen Kenneth W. Yip,1,4 Xinliang Mao,5 P.Y. Billie Au,1, 6 David W. Hedley,1, 4,7 Sue Chow,1,4 Shadi Dalili,2,5 Joseph D. Mocanu,1,4 Carlo Bastianutto,1,4 Aaron Schimmer,1, 5,7 and Fei-Fei Liu1, 3,4, 8 Abstract Purpose:This study aims to identify a novel therapeutic agent for head and neck cancer and to evaluate its antitumor efficacy. Experimental Design: A cell-based and phenotype-driven high-throughput screening of f2,400 biologically active or clinically used compounds was done using a tetrazolium-based assay on FaDu (hypopharyngeal squamous cancer) and NIH 3T3 (untransformed mouse embryonic fibroblast) cells, with secondary screening done on C666-1 (nasopharyngeal cancer) and GM05757 (primary normal human fibroblast) lines. The ‘‘hit’’ compound was assayed for efficacy in combination with standard therapeutics on a panel of human cancer cell lines. Furthermore, its mode of action (using transmission electron microscopy and flow cytometry) and its in vivo efficacy (using xenograft models) were evaluated. Results: Benzethonium chloride was identified as a novel cancer-specific compound. For benzethonium (48-hour incubation), the dose required to reduce cell viability by 50% was 3.8 Amol/L in FaDu, 42.2 Amol/L in NIH 3T3, 5.3 Amol/L in C666-1, and 17.0 Amol/L in GM05757. In vitro, this compound did not interfere with the effects of cisplatin, 5-fluorouracil, or g-irradiation. Benzethonium chloride induced apoptosis and activated caspases after12hours.
    [Show full text]
  • Bar Soap with Cationic Agent
    (19) TZZ¥_ T (11) EP 3 187 575 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 05.07.2017 Bulletin 2017/27 C11D 3/48 (2006.01) C11D 10/04 (2006.01) C11D 1/62 (2006.01) (21) Application number: 16204784.9 (22) Date of filing: 16.12.2016 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • JABCZYNSKI, Christopher GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO AZ 85719, Tucson, (US) PL PT RO RS SE SI SK SM TR •CONWAY,Mary J Designated Extension States: AZ 85022, Phoenix, (US) BA ME • SALAS, Juan Designated Validation States: Arizona 85213, Mesa, (US) MA MD • MACIAS, Jesus Arizona 85258, Scottsdale, (US) (30) Priority: 29.12.2015 US 201514982797 (74) Representative: Ludwig, Brigitte et al (71) Applicant: The Dial Corporation Henkel AG & Co. KGaA Scottsdale, AZ 85255 (US) CLI Patents 40191 Düsseldorf (DE) (54) BAR SOAP WITH CATIONIC AGENT (57) Composition of matter useful for cleaning and method of making thereof. The composition of matter comprising at least 10 wt. % of soap, where the soap is an anionic surfactant, and approximately 0.001 to approximately 1.0 wt. % of a cationic agent that is a quaternary amine. EP 3 187 575 A2 Printed by Jouve, 75001 PARIS (FR) EP 3 187 575 A2 Description Field of the invention 5 [0001] The present invention generally relates to solid bar soaps, and more particularly relates to solid bar soaps that contain anionic soap and a cationic active component.
    [Show full text]